Fibrinogen Concentrate (Human) - Efficacy and Safety Study

CSL Behring

Status and phase: Withdrawn; Phase 3

Conditions: Hypofibrinogenemia; Afibrinogenemia; Fibrinogen Deficiency

Treatments: Biological: Cryoprecipitate; Biological: Fibrinogen Concentrate, Human (FCH)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00916656

BI3023_3001

1475 (Other Identifier)

2007-004088-22 (EudraCT Number)

Details and patient eligibility

About

This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human).

It is estimated that 150-300 patients in the U.S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy.

The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia), expected to require treatment for bleeding
• Presenting with an episode of acute bleeding (either spontaneous or after trauma) not requiring surgery
• Provide informed consent

Exclusion criteria

• Life expectancy < 6 months
• Bleeding disorder other than congenital fibrinogen deficiency, but including dysfibrinogenemia
• Treatment with any investigational medicinal product (IMP) in the 30 days prior to enrollment
• Treatment with any fibrinogen concentrate or other fibrinogen containing blood product in the 2 weeks prior to enrollment
• Treatment with any coagulation active drug (i.e., non-steroidal-antirheumatics, warfarin, cumarin derivates, platelet aggregation inhibitors) in 1 week prior to enrollment or as a planned or expected medication during the time period from Day 1 until 24 hours after the last FCH infusion
• Presence or history of hypersensitivity to FCH
• Presence or history of deep vein thrombosis or pulmonary embolism within 1 year prior to enrollment
• Presence or history of arterial thrombosis within 1 year prior to enrollment
• Presence or history of hypersensitivity to human plasma proteins
• Presence or history of esophageal varicose bleeding
• End stage liver disease (i.e., Child Pugh score B or C)
• Planned or expected surgery (i.e., for bleedings from aneurysm or splenic rupture)
• Pregnancy, or an intention to become pregnant during the study
• Currently breast-feeding, or with the intention of breast-feeding during the study
• Human immunodeficiency virus (HIV) positive
• Polytrauma, present or within 6 months prior to enrollment
• Suspicion of an anti-fibrinogen inhibitor as indicated by previous in-vivo recovery (IVR), if available (< 0.5 (mg/dL)/(mg/kg))
• Previous inclusion and treatment in the prospective part of the study
• Participation in any clinical study in the 30 days prior to enrollment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Prospective Arm

Experimental group

Treatment:

Biological: Fibrinogen Concentrate, Human (FCH)

Historical Control

Other group

Treatment:

Biological: Cryoprecipitate